Custom Setmelanotide CAS 920014-72-8 from China Suppliers and Factory for Genetic Obesity Treatment Manufacturers, Quotes
Setmelanotide is a groundbreaking melanocortin-4 receptor (MC4R) agonist, specifically designed to address rare genetic obesity disorders resulting from unique gene mutations. By activating the MC4R pathway in the hypothalamus, Setmelanotide plays a critical role in regulating hunger, energy expenditure, and weight management, effectively restoring energy balance for affected patients, **Key Features:**, **Mechanism of Action:** Setmelanotide selectively stimulates the MC4R, replicating the benefits of the natural hormone α-melanocyte-stimulating hormone (α-MSH). This action significantly reduces feelings of hunger while enhancing satiety, **Administration Method:** The product is administered via a subcutaneous injection once daily, providing a convenient treatment option for patients, **Primary Target Diseases:**, - POMC deficiency obesity (including conditions related to PCSK1 deficiency), - LEPR deficiency obesity, - BBSome gene-related obesity, such as Bardet-Biedl syndrome, As a leading product among suppliers in China, Setmelanotide is manufactured in state-of-the-art factories, ensuring high-quality standards and efficacy for patients seeking solutions for their obesity disorders
Setmelanotide is a first-in-class melanocortin-4 receptor (MC4R) agonist used to treat a rare genetic obesity disorder caused by a specific gene defect. It helps restore energy balance and weight control in patients by activating the MC4R pathway in the hypothalamus (which plays a central role in regulating hunger, energy expenditure, and weight).
Key Features
Mechanism of action: Selectively activates MC4R, mimicking the effects of the natural hormone α-melanocyte-stimulating hormone (α-MSH), reducing hunger and increasing satiety.
Administration method: Subcutaneous injection once daily.
BBSome gene-related obesity (such as Bardet-Biedl syndrome)
Therapeutic Areas
Setmelanotide primarily focuses on rare genetic obesity disorders, specifically including:
Monogenic Obesity:
POMC/PCSK1 deficiency: Patients have insufficient activation of the MC4R pathway due to mutations in the POMC or PCSK1 genes, which manifests as early severe obesity, adrenal insufficiency, etc.
LEPR deficiency: A defect in the leptin receptor leads to the failure of the leptin signaling pathway, causing intense hunger and uncontrolled weight gain.
Syndrome-related Obesity:
Bardet-Biedl syndrome (BBS): A multi-system ciliary disorder that is often accompanied by severe obesity, retinopathy, polydactyly, etc.
Alström syndrome (clinical trial phase): A multisystemic disease similar to BBS, accompanied by early obesity and metabolic abnormalities.
Other MC4R Pathway-related Obesity:
Further research is underway on other gene variants involving the MC4R pathway (such as SH2B1, NCOA1, etc.).
Outlook & Development
1. Current Market & Clinical Standing
Approved indications: FDA and EMA approved for use in obese patients aged 6 years and older with POMC/PCSK1/LEPR deficiency or BBS.
Efficacy data: In pivotal clinical trials, most patients experienced significant weight loss (≥10%) and substantial improvement in hunger scores.
Commercialization progress: As a rare disease treatment, it is priced high, but accessibility is gradually being expanded through health insurance negotiations.
2. Expansion of the R&D Pipeline
Generalized MC4R pathway obesity: The TEMPO registry study explores the therapeutic effects on patients with other MC4R pathway gene variants, and may expand the scope of indications in the future.
Exploring combination therapies: When used in combination with metabolic drugs such as GLP-1 receptor agonists, it may be effective for a wider range of obese individuals.
3. Challenges & Opportunities
Small patient population: Market size is limited by the indication for rare diseases. Long-term real-world data is needed.
Administration method: Daily injection may affect compliance; oral formulation development has not yet made a breakthrough.
Competitive landscape: GLP-1 drugs dominate general obesity; setmelanotide needs to consolidate its irreplaceable position in precision medicine.
Pediatric market: Growing demand for early intervention for rare childhood obesity.
4. Market Prospects
Short-term: Solidify its position as the standard treatment in the field of rare hereditary obesity, with penetration increasing as genetic testing becomes more widespread.
Long-term: Market potential could increase if expanded to a wider range of MC4R-related obesity subtypes or combination therapies. Research may lead to a new generation of oral or long-acting formulations.
Conclusion
In summary, Setmelanotide is a breakthrough therapy in the field of rare genetic obesity, filling a clinical gap by precisely targeting the MC4R pathway. Its future value will depend on the expansion of its indications, the development of combination therapies, and its deeper positioning in precision obesity medicine.
Frequently Asked Questions
What is Setmelanotide?
Setmelanotide is a first-in-class melanocortin-4 receptor (MC4R) agonist designed to treat rare genetic obesity disorders by restoring energy balance and weight control.
How does Setmelanotide work in the body?
It selectively activates the MC4R pathway in the hypothalamus, mimicking the natural hormone α-MSH. This mechanism helps to significantly reduce hunger and increase satiety.
What are the primary diseases targeted by this medication?
It primarily targets POMC/PCSK1 deficiency obesity, LEPR deficiency obesity, and BBSome gene-related obesity (such as Bardet-Biedl syndrome).
How is Setmelanotide administered to patients?
The medication is currently administered via a subcutaneous injection once daily.
What are the main challenges for Setmelanotide in the market?
The main challenges include an extremely small patient population due to its rare disease indication, potential compliance issues with daily injections, and indirect competition from widely used GLP-1 obesity drugs.
What is the future outlook for Setmelanotide?
The future outlook is promising, heavily depending on expanding its indications to other MC4R-related obesity subtypes, developing combination therapies (e.g., with GLP-1 agonists), and potentially creating oral or long-acting formulations.
Thin
